Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bacterial Infections and Mycoses
  Free Subscription

Articles published in
Nat Med
    October 2026
  1. WURSTLE S, Lieberknecht-Jouy SC, Duchting A, Lossner H, et al
    A consensus-based guideline for personalized bacteriophage therapy.
    Nat Med. 2026;32:3578-3594.
    >> Share

    September 2026
  2. KETHIDI N, Pothukuchi S, Aleman A, Charytonowicz D, et al
    Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.
    Nat Med. 2026 Sep 23. doi: 10.1038/s41591-026-04632.
    >> Share

    August 2026
  3. PORTER ML, Martorell A, Sayed CJ, Bechara FG, et al
    Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
    Nat Med. 2026;32:3071-3081.
    >> Share

    July 2026
  4. MADHI SA, Snaggs H, Skogeby Z, Feng Y, et al
    Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.
    Nat Med. 2026 Jul 28. doi: 10.1038/s41591-026-04558.
    >> Share

  5. BETHLEHEM L, Bartu L, Marke G, Mar P, et al
    15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.
    Nat Med. 2026;32:2546-2555.
    >> Share

    April 2026
  6. TRAJMAN A, Campbell JR
    The ghost of tuberculosis past.
    Nat Med. 2026 Apr 22. doi: 10.1038/s41591-026-04356.
    >> Share

    March 2026
  7. CERQUEIRA-SILVA T, Boaventura VS, Paixao ES, Sanchez M, et al
    Long-term risk of death after tuberculosis diagnosis and treatment.
    Nat Med. 2026 Mar 19. doi: 10.1038/s41591-026-04294.
    >> Share

    January 2026

  8. A low-toxicity linezolid analog has potential for use in all patients with tuberculosis.
    Nat Med. 2026 Jan 15. doi: 10.1038/s41591-025-04188.
    >> Share

  9. DONOVAN J, Duc Bang N, Dong HKT, Ho DTN, et al
    Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.
    Nat Med. 2026 Jan 15. doi: 10.1038/s41591-025-04138.
    >> Share

  10. CROWLEY BM, Boshoff HI, Boving A, Tan VY, et al
    Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis.
    Nat Med. 2026 Jan 13. doi: 10.1038/s41591-025-04164.
    >> Share

  11. VAN LIESHOUT TITAN A, Dodd PJ, Cohen T, Menzies NA, et al
    Estimating the number of incorrect tuberculosis diagnoses in low- and middle-income countries.
    Nat Med. 2026 Jan 7. doi: 10.1038/s41591-025-04097.
    >> Share

  12. BRYANT JA, Vulic M, Walsh EA, Allen EG Jr, et al
    The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.
    Nat Med. 2026;32:186-196.
    >> Share

    December 2025
  13. LIESENFELD O, Arora S, Aufderheide TP, Clements CM, et al
    Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis.
    Nat Med. 2025;31:4044-4054.
    >> Share

    October 2025
  14. CHEN WH, Barnes RS, Sikorski MJ, Datar R, et al
    A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2025 Oct 8. doi: 10.1038/s41591-025-04003.
    >> Share

  15. PEREZ-SAEZ J, Zheng Q, Kaminsky J, Zou K, et al
    Geographical shifting of cholera burden in Africa and its implications for disease control.
    Nat Med. 2025;31:3380-3387.
    >> Share

    September 2025
  16. KEELEY AJ, Camara FE, Armitage EP, de Crombrugghe G, et al
    Publisher Correction: Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.
    Nat Med. 2025 Sep 24. doi: 10.1038/s41591-025-04017.
    >> Share

  17. PARK JY, Georges D, Alberts CJ, Bray F, et al
    Global lifetime estimates of expected and preventable gastric cancers across 185 countries.
    Nat Med. 2025;31:3020-3027.
    >> Share

    August 2025
  18. KEELEY AJ, Camara FE, Armitage EP, de Crombrugghe G, et al
    Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.
    Nat Med. 2025 Aug 8. doi: 10.1038/s41591-025-03868.
    >> Share

  19. LIANG Z, Liu S, Guo W, Deng Z, et al
    Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial.
    Nat Med. 2025;31:2673-2681.
    >> Share

    July 2025
  20. ZHOU H, Jia C, Shen P, Huang C, et al
    Genomic census of invasive nontyphoidal Salmonella infections reveals global and local human-to-human transmission.
    Nat Med. 2025;31:2325-2334.
    >> Share

    June 2025
  21. DARTOIS VA, Mizrahi V, Savic RM, Silverman JA, et al
    Strategies for shortening tuberculosis therapy.
    Nat Med. 2025;31:1765-1775.
    >> Share

    May 2025
  22. CHAN BK, Stanley GL, Kortright KE, Vill AC, et al
    Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Nat Med. 2025;31:1494-1501.
    >> Share

    April 2025
  23. GILBERT JA, Azad MB, Backhed F, Blaser MJ, et al
    Clinical translation of microbiome research.
    Nat Med. 2025;31:1099-1113.
    >> Share

    January 2025
  24. JESUS GS, Gestal PFPS, Silva AF, Cavalcanti DM, et al
    Effects of conditional cash transfers on tuberculosis incidence and mortality according to race, ethnicity and socioeconomic factors in the 100 Million Brazilian Cohort.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03381.
    >> Share

  25. MENON R, Bhattarai SK, Crossette E, Prince AL, et al
    Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection.
    Nat Med. 2025;31:223-234.
    >> Share

    November 2024
  26. PAN KF, Li WQ, Zhang L, Liu WD, et al
    Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.
    Nat Med. 2024;30:3250-3260.
    >> Share

    August 2024
  27. ZHAI B, Liao C, Jaggavarapu S, Tang Y, et al
    Antifungal heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infections.
    Nat Med. 2024 Aug 2. doi: 10.1038/s41591-024-03183.
    >> Share

    June 2024
  28. CLIFF M, Welaga P, Mohammed N, Ansah P, et al
    Strategies for controlling pneumococcal disease and outbreaks during humanitarian emergencies.
    Nat Med. 2024;30:1515-1516.
    >> Share

    May 2024
  29. MENTZER AJ, Dilthey AT, Pollard M, Gurdasani D, et al
    High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02944.
    >> Share

    April 2024

  30. Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
    Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
    >> Share

    March 2024
  31. NUERMBERGER EL, Chaisson RE
    Restocking the tuberculosis drug arsenal.
    Nat Med. 2024 Mar 8. doi: 10.1038/s41591-024-02840.
    >> Share

  32. XU H, Zou K, Dent J, Wiens KE, et al
    Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852.
    >> Share

  33. HEGDE ST, Khan AI, Perez-Saez J, Khan II, et al
    Clinical surveillance systems obscure the true cholera infection burden in an endemic region.
    Nat Med. 2024;30:888-895.
    >> Share

  34. KHAN S, Guo X, Awan UA
    Pakistan is failing in maternal and neonatal tetanus elimination.
    Nat Med. 2024;30:615.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016